Lupin announced today the launch of Meloxicam Capsules, 5 mg, and 10 mg, having received an approval from the United States
Food and Drug Administration.
Meloxicam Capsules, 5 mg and 10 mg, is the generic equivalent of Vivlodex® Capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc., and indicated for management of osteoarthritis (OA) pain.
Meloxicam Capsules (RLD: Vivlodex®) had an annual sales of approximately USD 11 million in the U.S. (IQVIA
MAT October 2020).